Atropos Health has secured $33 million in series B funding to enhance its AI-powered real-world evidence platform, Geneva OS, and its chatbot, ChatRWD. Founded in 2019, the company aims to bridge the healthcare evidence gap by rapidly generating high-quality clinical studies. The funding, led by Valtruis and supported by notable investors, will also support strategic partnerships with pharmaceutical companies and international expansion efforts.